Affimed N.V IPO year
What is the IPO year of Affimed N.V?
The IPO year of Affimed N.V. is 2014
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on NASDAQ compared to Affimed N.V
What does Affimed N.V do?
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Companies with ipo year similar to Affimed N.V
- Australian REIT Income Fund has IPO year of 2013
- Brookfield Asset Management PRF SH CL A SE37 has IPO year of 2013
- Modern Meat has IPO year of 2013
- Blue Capital Reinsurance Ltd has IPO year of 2013
- Siyata Mobile has IPO year of 2013
- Mirati Therapeutics Inc has IPO year of 2013
- Affimed N.V has IPO year of 2014
- Glaukos has IPO year of 2015
- UBS ETFs Public - MSCI ACWI SF UCITS ETF has IPO year of 2015
- Acasta Enterprises has IPO year of 2015
- Faron Pharmaceuticals Oy has IPO year of 2015
- GreenPower Motor Co has IPO year of 2015
- Sunrun Inc has IPO year of 2015